TDMS Study 05040-02 Pathology Tables
INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) HYDROQUINONE NTP Experiment-Test: 05040-02 Report: PEIRPT05 Study Type: CHRONIC Date: 09/05/94 Route: GAVAGE Time: 11:58:40 Facility: American Biogenics Corp. Chemical CAS #: 000123319 Lock Date: None Cage Range: All Reasons For Removal: All Removal Date Range: All Treatment Groups: Include All a Number of animals examined microscopically at site and number of animals with lesion Page 1 NTP Experiment-Test: 05040-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC HYDROQUINONE Date: 09/05/94 Route: GAVAGE Time: 11:58:40 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE FEMALE VEHICLE 50 MG/KG 100MG/KG CONTROL ____________________________________________________________________________________________________________________________________ DISPOSITION SUMMARY Animals Initially in Study 65 65 65 Scheduled Sacrifice 10 10 10 Early Deaths Moribund 7 11 6 Dead 11 5 9 Accident 4 Survivors Terminal Sacrifice 37 39 36 Animals Examined Microscopically 55 55 55 ____________________________________________________________________________________________________________________________________ ALIMENTARY SYSTEM Gallbladder (50) (12) (48) Intestine Large, Cecum (52) (13) (53) Intestine Large, Colon (52) (14) (52) Intestine Small, Duodenum (52) (15) (51) Serosa, Fibrosarcoma, Metastatic, Mesentery 1 (7%) Intestine Small, Ileum (49) (14) (52) Intestine Small, Jejunum (52) (12) (52) Liver (55) (55) (55) Cholangiocarcinoma, Metastatic 1 (2%) Hemangioma 1 (2%) 1 (2%) Hemangiosarcoma 1 (2%) Hepatocellular Carcinoma 1 (2%) 2 (4%) 2 (4%) Hepatocellular Adenoma 2 (4%) 11 (20%) 11 (20%) Hepatocellular Adenoma, Multiple 4 (7%) 1 (2%) Histiocytic Sarcoma 1 (2%) Mesentery (19) (12) (4) Cholangiocarcinoma, Metastatic 1 (8%) Fibrosarcoma 1 (8%) Fibrosarcoma, Multiple 1 (8%) Pancreas (54) (16) (53) Fibrosarcoma, Early Invasion, Metastatic, Mesentery 1 (6%) Salivary Glands (54) (54) (54) Histiocytic Sarcoma 1 (2%) Stomach (54) (17) (55) Stomach, Forestomach (54) (17) (55) Squamous Cell Papilloma 1 (6%) Stomach, Glandular (53) (16) (55) ____________________________________________________________________________________________________________________________________ Page 2 NTP Experiment-Test: 05040-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC HYDROQUINONE Date: 09/05/94 Route: GAVAGE Time: 11:58:40 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE FEMALE VEHICLE 50 MG/KG 100MG/KG CONTROL ____________________________________________________________________________________________________________________________________ CARDIOVASCULAR SYSTEM Heart (55) (17) (55) ____________________________________________________________________________________________________________________________________ ENDOCRINE SYSTEM Adrenal Gland (55) (13) (55) Capsule, Cholangiocarcinoma, Metastatic 1 (8%) Adrenal Gland, Cortex (55) (13) (55) Adrenal Gland, Medulla (51) (11) (52) Pheochromocytoma Malignant 1 (2%) Pheochromocytoma Benign 1 (2%) Islets, Pancreatic (51) (15) (52) Pituitary Gland (52) (29) (52) Pars Distalis, Adenoma 11 (21%) 14 (48%) 11 (21%) Pars Distalis, Carcinoma 1 (2%) 2 (7%) Pars Intermedia, Adenoma 1 (2%) 1 (2%) Thyroid Gland (55) (55) (55) Follicular Cell, Adenoma 3 (5%) 5 (9%) 6 (11%) Follicular Cell, Carcinoma 1 (2%) ____________________________________________________________________________________________________________________________________ GENERAL BODY SYSTEM Tissue NOS (1) (1) Sarcoma, Poorly Differentiated 1 (100%) ____________________________________________________________________________________________________________________________________ GENITAL SYSTEM Ovary (55) (53) (54) Adenoma 1 (2%) Cystadenoma 1 (2%) Osteosarcoma, Metastatic, Bone 1 (2%) Teratoma 1 (2%) Uterus (54) (29) (55) Hemangioma 1 (3%) Polyp Stromal 1 (3%) ____________________________________________________________________________________________________________________________________ HEMATOPOIETIC SYSTEM Bone Marrow (55) (16) (54) Lymph Node (55) (22) (54) Lumbar, Osteosarcoma, Metastatic, Bone 1 (5%) Pancreatic, Histiocytic Sarcoma 1 (2%) Lymph Node, Mandibular (50) (16) (49) Page 3 NTP Experiment-Test: 05040-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC HYDROQUINONE Date: 09/05/94 Route: GAVAGE Time: 11:58:40 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE FEMALE VEHICLE 50 MG/KG 100MG/KG CONTROL ____________________________________________________________________________________________________________________________________ HEMATOPOIETIC SYSTEM - cont Histiocytic Sarcoma 1 (2%) Lymph Node, Mesenteric (52) (17) (52) Histiocytic Sarcoma 1 (2%) Renal, Cholangiocarcinoma, Metastatic 1 (6%) Spleen (55) (22) (55) Capsule, Cholangiocarcinoma, Metastatic 1 (5%) Thymus (44) (13) (47) ____________________________________________________________________________________________________________________________________ INTEGUMENTARY SYSTEM Mammary Gland (52) (20) (53) Adenocarcinoma 3 (6%) 5 (25%) 2 (4%) Cholangiocarcinoma, Multiple, Metastatic 1 (5%) Thoracic, Hepatocellular Carcinoma, Metastatic, Liver 1 (5%) Skin (55) (16) (55) Basal Cell Carcinoma 1 (2%) Subcutaneous Tissue, Fibrosarcoma 1 (2%) 1 (6%) Subcutaneous Tissue, Hepatocellular Carcinoma, Metastatic, Liver 1 (6%) Tail, Neurofibrosarcoma 1 (2%) Thoracic, Subcutaneous Tissue, Hemangiosarcoma 1 (2%) ____________________________________________________________________________________________________________________________________ MUSCULOSKELETAL SYSTEM Bone (55) (16) (55) Lumbar, Vertebra, Osteosarcoma 1 (6%) Vertebra, Cholangiocarcinoma, Metastatic 1 (6%) Skeletal Muscle (2) (1) Abdominal, Fibrosarcoma, Early Invasion, Metastatic, Mesentery 1 (50%) Abdominal, Diaphragm, Cholangiocarcinoma, Metastatic 1 (50%) ____________________________________________________________________________________________________________________________________ NERVOUS SYSTEM Brain (55) (16) (55) Carcinoma, Extension, Metastatic, Pituitary Gland 1 (2%) 1 (6%) Cerebrum, Oligodendroglioma Malignant 1 (2%) ____________________________________________________________________________________________________________________________________ Page 4 NTP Experiment-Test: 05040-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC HYDROQUINONE Date: 09/05/94 Route: GAVAGE Time: 11:58:40 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE FEMALE VEHICLE 50 MG/KG 100MG/KG CONTROL ____________________________________________________________________________________________________________________________________ RESPIRATORY SYSTEM Lung (55) (55) (55) Alveolar/Bronchiolar Adenoma 3 (5%) 6 (11%) 1 (2%) Alveolar/Bronchiolar Adenoma, Multiple 1 (2%) Alveolar/Bronchiolar Carcinoma 1 (2%) 2 (4%) Basal Cell Carcinoma, Metastatic 1 (2%) Carcinoma, Metastatic 1 (2%) Hepatocellular Carcinoma, Metastatic, Liver 1 (2%) Osteosarcoma, Metastatic, Bone 1 (2%) Trachea (54) (16) (55) ____________________________________________________________________________________________________________________________________ SPECIAL SENSES SYSTEM Ear (1) Canal, External Ear, Squamous Cell Carcinoma 1 (100%) Harderian Gland (3) (3) (7) Adenoma 2 (67%) 2 (67%) 2 (29%) Carcinoma 2 (29%) ____________________________________________________________________________________________________________________________________ URINARY SYSTEM Kidney (55) (16) (55) Hepatocellular Carcinoma, Metastatic 1 (6%) Osteosarcoma, Metastatic, Bone 1 (6%) Capsule, Cholangiocarcinoma, Metastatic 1 (6%) Renal Tubule, Adenoma 1 (2%) 1 (2%) Urinary Bladder (53) (15) (54) ____________________________________________________________________________________________________________________________________ SYSTEMIC LESIONS Multiple Organs *(55) *(55) *(55) Histiocytic Sarcoma 1 (2%) Lymphoma Malignant 3 (5%) 1 (2%) 3 (5%) Lymphoma Malignant Histiocytic 1 (2%) 1 (2%) Lymphoma Malignant Lymphocytic 14 (25%) 7 (13%) 9 (16%) Lymphoma Malignant Mixed 7 (13%) 5 (9%) 6 (11%) Lymphoma Malignant Undifferentiated Cell 1 (2%) ____________________________________________________________________________________________________________________________________ * Number of animals with any tissue examined microscopically Page 5 NTP Experiment-Test: 05040-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC HYDROQUINONE Date: 09/05/94 Route: GAVAGE Time: 11:58:40 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE FEMALE VEHICLE 50 MG/KG 100MG/KG CONTROL ____________________________________________________________________________________________________________________________________ TUMOR SUMMARY Total Animals with Primary Neoplasms (b) 43 42 39 Total Primary Neoplasms 64 76 67 Total Animals with Benign Neoplasms 21 33 27 Total Benign Neoplasms 26 47 36 Total Animals with Malignant Neoplasms 31 21 27 Total Malignant Neoplasms 38 29 31 Total Animals with Metastatic Neoplasms 2 4 1 Total Metastatic Neoplasm 2 21 1 Total Animals with Malignant Neoplasms Uncertain Primary Site Total Animals with Neoplasms Uncertain- Benign or Malignant Total Uncertain Neoplasms ____________________________________________________________________________________________________________________________________ a Number of animals examined microscopically at site and number of animals with lesion b Primary tumors: all tumors except metastatic tumors Page 6 NTP Experiment-Test: 05040-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC HYDROQUINONE Date: 09/05/94 Route: GAVAGE Time: 11:58:40 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE MALE VEHICLE 50 MG/KG 100MG/KG CONTROL ____________________________________________________________________________________________________________________________________ DISPOSITION SUMMARY Animals Initially in Study 65 65 65 Scheduled Sacrifice 10 10 10 Early Deaths Moribund 12 10 5 Dead 10 7 14 Survivors Terminal Sacrifice 33 37 36 Wrong Sex 1 Animals Examined Microscopically 55 54 55 ____________________________________________________________________________________________________________________________________ ALIMENTARY SYSTEM Gallbladder (44) (11) (48) Intestine Large, Cecum (49) (13) (49) Intestine Large, Colon (49) (14) (48) Intestine Large, Rectum (50) (15) (52) Serosa, Carcinoid Tumor Benign 1 (2%) Intestine Small, Ileum (48) (10) (47) Adenocarcinoma 1 (2%) Intestine Small, Jejunum (50) (13) (45) Liver (55) (54) (55) Fibrosarcoma, Metastatic, Skin 1 (2%) Hemangioma 1 (2%) Hemangioma, Marked 1 (2%) Hemangiosarcoma 1 (2%) 1 (2%) 2 (4%) Hepatocellular Carcinoma 12 (22%) 11 (20%) 7 (13%) Hepatocellular Carcinoma, Multiple 1 (2%) Hepatocellular Adenoma 9 (16%) 15 (28%) 15 (27%) Hepatocellular Adenoma, Multiple 6 (11%) 5 (9%) Sinusoid, Sarcoma 1 (2%) Mesentery (6) (4) (5) Alveolar/Bronchiolar Carcinoma, Metastatic, Lung 1 (17%) Pancreas (54) (15) (53) Salivary Glands (55) (16) (55) Stomach, Forestomach (55) (15) (53) Squamous Cell Papilloma 2 (4%) ____________________________________________________________________________________________________________________________________ Page 7 NTP Experiment-Test: 05040-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC HYDROQUINONE Date: 09/05/94 Route: GAVAGE Time: 11:58:40 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE MALE VEHICLE 50 MG/KG 100MG/KG CONTROL ____________________________________________________________________________________________________________________________________ CARDIOVASCULAR SYSTEM Heart (55) (17) (55) Alveolar/Bronchiolar Carcinoma, Metastatic, Lung 1 (2%) ____________________________________________________________________________________________________________________________________ ENDOCRINE SYSTEM Adrenal Gland (55) (53) (54) Adrenal Gland, Cortex (55) (52) (54) Adenoma 2 (4%) 2 (4%) Adrenal Gland, Medulla (54) (52) (54) Pheochromocytoma Benign 1 (2%) 3 (6%) Pituitary Gland (50) (14) (50) Pars Distalis, Adenoma 3 (6%) Thyroid Gland (55) (53) (54) Follicular Cell, Adenoma 2 (4%) 1 (2%) 2 (4%) ____________________________________________________________________________________________________________________________________ GENERAL BODY SYSTEM Tissue NOS (1) (1) Carcinoma 1 (100%) ____________________________________________________________________________________________________________________________________ GENITAL SYSTEM Epididymis (54) (17) (54) Prostate (55) (17) (55) Seminal Vesicle (55) (17) (55) Testes (55) (18) (55) Interstitial Cell, Adenoma 1 (2%) 3 (5%) ____________________________________________________________________________________________________________________________________ HEMATOPOIETIC SYSTEM Lymph Node (55) (29) (55) Alveolar/Bronchiolar Carcinoma, Metastatic, Lung 1 (2%) Lymph Node, Mandibular (52) (17) (51) Lymph Node, Mesenteric (54) (23) (50) Spleen (55) (52) (54) Thymus (39) (10) (42) ____________________________________________________________________________________________________________________________________ Page 8 NTP Experiment-Test: 05040-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC HYDROQUINONE Date: 09/05/94 Route: GAVAGE Time: 11:58:40 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE MALE VEHICLE 50 MG/KG 100MG/KG CONTROL ____________________________________________________________________________________________________________________________________ INTEGUMENTARY SYSTEM Skin (55) (33) (55) Fibroma 1 (2%) 1 (3%) Fibrosarcoma 2 (4%) 1 (3%) 1 (2%) Squamous Cell Papilloma 1 (2%) Subcutaneous Tissue, Fibroma 1 (2%) 1 (3%) Subcutaneous Tissue, Fibroma, Multiple 1 (3%) Subcutaneous Tissue, Fibrosarcoma 5 (9%) 8 (24%) 2 (4%) Subcutaneous Tissue, Hemangiosarcoma 1 (2%) Subcutaneous Tissue, Neurofibroma 1 (2%) Subcutaneous Tissue, Sarcoma 1 (2%) 3 (9%) ____________________________________________________________________________________________________________________________________ MUSCULOSKELETAL SYSTEM Bone (54) (32) (55) Osteosarcoma 1 (2%) Skeletal Muscle (3) Intercostal, Alveolar/Bronchiolar Carcinoma, Metastatic, Lung 1 (33%) ____________________________________________________________________________________________________________________________________ NERVOUS SYSTEM Brain (55) (17) (55) ____________________________________________________________________________________________________________________________________ RESPIRATORY SYSTEM Lung (55) (31) (55) Alveolar/Bronchiolar Adenoma 5 (9%) 9 (29%) 3 (5%) Alveolar/Bronchiolar Adenoma, Multiple 1 (2%) 1 (2%) Alveolar/Bronchiolar Carcinoma 8 (15%) 4 (13%) 6 (11%) Hepatocellular Carcinoma, Metastatic, Liver 5 (9%) 3 (5%) Nose (55) (17) (55) ____________________________________________________________________________________________________________________________________ SPECIAL SENSES SYSTEM Ear (1) Pinna, Histiocytic Sarcoma 1 (100%) Harderian Gland (5) (2) (7) Adenoma 5 (100%) 2 (100%) 6 (86%) ____________________________________________________________________________________________________________________________________ Page 9 NTP Experiment-Test: 05040-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC HYDROQUINONE Date: 09/05/94 Route: GAVAGE Time: 11:58:40 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE MALE VEHICLE 50 MG/KG 100MG/KG CONTROL ____________________________________________________________________________________________________________________________________ URINARY SYSTEM Kidney (55) (17) (55) Renal Tubule, Carcinoma 1 (2%) Urinary Bladder (54) (15) (55) ____________________________________________________________________________________________________________________________________ SYSTEMIC LESIONS Multiple Organs *(55) *(54) *(55) Histiocytic Sarcoma 1 (2%) Lymphoma Malignant Histiocytic 2 (4%) 2 (4%) Lymphoma Malignant Lymphocytic 4 (7%) 9 (17%) 4 (7%) Lymphoma Malignant Mixed 2 (4%) 1 (2%) ____________________________________________________________________________________________________________________________________ * Number of animals with any tissue examined microscopically Page 10 NTP Experiment-Test: 05040-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC HYDROQUINONE Date: 09/05/94 Route: GAVAGE Time: 11:58:40 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE MALE VEHICLE 50 MG/KG 100MG/KG CONTROL ____________________________________________________________________________________________________________________________________ TUMOR SUMMARY Total Animals with Primary Neoplasms (b) 39 46 44 Total Primary Neoplasms 79 84 69 Total Animals with Benign Neoplasms 23 31 29 Total Benign Neoplasms 38 41 41 Total Animals with Malignant Neoplasms 30 34 23 Total Malignant Neoplasms 41 43 28 Total Animals with Metastatic Neoplasms 7 4 Total Metastatic Neoplasm 9 4 Total Animals with Malignant Neoplasms Uncertain Primary Site Total Animals with Neoplasms Uncertain- Benign or Malignant Total Uncertain Neoplasms ____________________________________________________________________________________________________________________________________ a Number of animals examined microscopically at site and number of animals with lesion b Primary tumors: all tumors except metastatic tumors Page 11 ------------------------------------------------------------ ---------- END OF REPORT ---------- ------------------------------------------------------------ --multipart-boundary Content-type: text/plain Range: bytes 65389-65389/65389 --multipart-boundary--